Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07575308 | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | PHASE2 | NOT YET_RECRUITING | 24 | — | — | May 22, 2026 | Nov 29, 2028 | May 14, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| ALN-6400 (Treatment Group A) | EXPERIMENTAL | Participants will be administered multiple doses of ALN-6400. |
| ALN-6400 (Treatment Group B) | EXPERIMENTAL | Participants will be administered multiple doses of ALN-6400. |
| Name | Type | Description |
|---|---|---|
| ALN-6400 | DRUG | ALN-6400 will be administered subcutaneously (SC). |
Inclusion Criteria - * Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Type 2, Type 3, and platelet-type VWD) and HMB for 2 cycles during screening Exclusion Criteria - * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times the u...